Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04354012 · ClinicalTrials.gov registry record · Phase 2
Hidradenitis Suppurativa Wound Care
A Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04354012: Completed Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Wake Forest University Health Sciences.
NCT04354012 is a Phase 2 study of Hidradenitis Suppurativa (HS) that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 5 participants, below the 180-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04354012, a Phase 2 study of Hidradenitis Suppurativa (HS), has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform \[ovine forestomach\], Hydrofera Blue \[methylene blue and gentian violet\], and Hypafix tape. a combination methylene blue, gentian violet, and ovine forestomach wound care product.
Primary Outcome
Asses the percent healing that occurs over 8 weeks of follow-up using Endoform and Hydrofera Blue products
Conditions Studied
Interventions
- COMBINATION_PRODUCT methylene blue, gentian violet, and ovine forestomach wound dressings
Study Locations (1)
North Carolina
- Wake Forest Health Sciences Dermatology - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-02-04 |
| Est. Completion | 2024-08-28 |
| Phase | Phase 2 |
What the finished NCT04354012 record still lists
NCT04354012 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 180-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 1 intervention - of which methylene blue, gentian violet, and ovine forestomach wound dressings is the first listed.
NCT04354012 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04354012 about?
NCT04354012 is a clinical study titled "Hidradenitis Suppurativa Wound Care". The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform \[ovine forestomach\], Hydrofera Blue \[methylene blue and gentian violet\], and Hypafix tape. a combination methylene blue, gentian violet, and ovine forestomach wound care produc...
What is the current status of trial NCT04354012?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2021-02-04. Estimated completion is 2024-08-28.
What conditions does trial NCT04354012 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT04354012?
The interventions under investigation include: methylene blue, gentian violet, and ovine forestomach wound dressings (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04354012?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04354012 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04354012's enrollment target sits among peer trials
5 13th of 12 the lowest of 12 other Hidradenitis Suppurativa (HS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa (HS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI